Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares Under 10b5-1 Plan

Director Richard A. Heyman of Enliven Therapeutics, Inc. sold 518 shares of common stock at an average price of $27.5373 per share on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc., sold 518 shares of common stock on October 1, 2024.
• The sale was executed under a Rule 10b5-1 trading plan adopted on July 17, 2023.
• The shares were sold at prices ranging from $27.52 to $27.54, with a weighted average sale price of $27.5373.
• Following the transaction, Heyman directly owns 128,585 shares.
• Heyman also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 27,918 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of insider trading.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates